Entero Healthcare Q2 FY27 Profit Climbs to Rs 455 Million

Revenue at Rs 20,870.75 Million; Net Profit at Rs 455.43 Million

Reader Takeaway: Strong double-digit top-line growth drives bottom-line expansion; integration of recent acquisitions remains a key focus area.

What just happened

Entero Healthcare Solutions has released its consolidated financial results for the quarter ended September 30, 2026. The company recorded a robust revenue growth of 32.8%, reaching Rs 20,870.75 million compared to Rs 15,709.48 million in the same period last year. Net profit attributable to owners saw a significant increase of 44.1%, totaling Rs 455.43 million. Basic Earnings Per Share (EPS) for the quarter stood at Rs 10.47, up from Rs 7.26 in the previous year.

Why this matters

The double-digit growth in both revenue and profit signals sustained demand in the pharmaceutical and surgical distribution segments. The performance highlights the company's ability to scale operations while simultaneously improving its bottom-line efficiency. Investors are observing these metrics to gauge the health of the company’s distribution network expansion.

ESOP Grant Details

Beyond financial results, the Board approved the grant of 49,712 options under the Entero Employee Stock Option Plan 2023. These options are priced at an exercise price of Rs 804 each. The vesting schedule spans one to four years, with an exercise window of eight years following the vesting date, indicating a long-term retention strategy for employees.

Risks to watch

As the company continues its growth trajectory, the primary focus for market participants is the successful integration of recent acquisitions. Managing debt and operational costs during this expansion phase is crucial to maintaining the current margin levels.

What to track next

Shareholders should look for management commentary regarding the sustainability of the current growth rates and any updates on capital allocation strategies following the integration of newly acquired businesses.